{
    "organizations": [],
    "uuid": "8f857d633682798913426f5ab8953cdd3c7bee76",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-athenex-receives-us-fda-orphan-dru/brief-athenex-receives-u-s-fda-orphan-drug-designation-for-oraxol-for-the-treatment-of-angiosarcoma-idUSASC09WH4",
    "ord_in_thread": 0,
    "title": "BRIEF-Athenex Receives U.S. FDA Orphan Drug Designation For Oraxol For The Treatment Of Angiosarcoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Athenex Inc:\n* ATHENEX, INC. RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR ORAXOL FOR THE TREATMENT OF ANGIOSARCOMA\n* ATHENEX INC - WILL BE INITIATING ANGIOSARCOMA CLINICAL STUDY SOON Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T20:02:00.000+03:00",
    "crawled": "2018-04-20T12:06:35.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "athenex",
        "inc",
        "athenex",
        "receives",
        "fda",
        "orphan",
        "drug",
        "designation",
        "oraxol",
        "treatment",
        "angiosarcoma",
        "athenex",
        "inc",
        "initiating",
        "angiosarcoma",
        "clinical",
        "study",
        "soon",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}